Antibodies against vascular endothelial growth factor receptor 2 (VEGFR2), encoding nucleic acid molecules and methods for treating an angiogenesis-related disease
US10465008B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 25, 2016 |
| Grant date | Nov 5, 2019 |
| Priority date | — |
| Expiry date | Nov 25, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel antibody against VEGFR2 for use in the prevention or treatment of macular degeneration and cancer, which are angiogenesis-related diseases. The antibody of the present invention is an antibody which specifically binds to VEGFR2 which is overexpressed in vascular endothelial cells. The antibody of the present invention has very low homology compared to the CDR sequences of conventional VEGFR2 target antibodies, and thus is unique in its sequence. Since the antibody of the present invention, when treated alone, has the ability to inhibit vascular endothelial cell growth equivalent to that of ramucirumab which is conventionally used, it is very effective to prevent or treat angiogenesis-related diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.